Drug Trial Radar · NCT04877522
Asciminib Roll-over Study
Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
347
Planned (sponsor's estimate)
Start
Aug 30, 2022
Primary completion
Aug 30, 2030
Study completion Aug 30, 2030
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- May 7, 2021
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 7 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a long term safety study for patients who have completed a Novartis sponsored asciminib study and are judged by the investigator to benefit from continued treatment
Conditions
- Chronic Myelogenous Leukemia
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Interventions
Asciminib single agentDrug
Taken orally, twice daily (BID) or once daily (QD), in fasting state
ImatinibDrug
Taken orally, once daily, in the morning with low-fat meal
NilotinibDrug
Taken orally, twice daily, on an empty stomach
BosutinibDrug
Taken orally, once daily, with food
DasatinibDrug
Taken orally, once daily in a fasted state, 1 or 2 hours before a meal
Asciminib single agent pediatric formulationDrug
Pediatric participants receive a body weight adjusted dose of 1.3 mg/kg of pediatric film coated granules with food twice daily (b.i.d.) or 2.6 mg/kg once daily (q.d.) in the morning.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with adverse events (AEs) and serious adverse events (SAEs)Time frame: 8 years
Locations
88 sites in 29 countries. Site status is shown where the registry gives one.
Michigan Med University of Michigan
Ann Arbor, Michigan · Recruiting
Washington University School Of Medicine-Siteman Cancer Ctr
St Louis, Missouri · Recruiting
Memorial Sloan Kettering
New York, New York · Recruiting
Oncology Hematology Care Inc
Cincinnati, Ohio · Recruiting
Oregon Health Sciences University
Portland, Oregon · Active not recruiting
Texas Oncology
Dallas, Texas · Recruiting
Uni Of TX MD Anderson Cancer Cntr
Houston, Texas · Recruiting
Huntsman Cancer Institute
Salt Lake City, Utah · Recruiting
Medical College of Wisconsin
Milwaukee, Wisconsin · Recruiting
Novartis Investigative Site
Capital Federal, Argentina · Recruiting
Novartis Investigative Site
CABA, Buenos Aires, Argentina · Recruiting
Novartis Investigative Site
Graz, Austria · Recruiting
Novartis Investigative Site
Vienna, Austria · Recruiting
Novartis Investigative Site
Rio de Janeiro, Rio de Janeiro, Brazil · Completed
Novartis Investigative Site
São Paulo, São Paulo, Brazil · Completed
Novartis Investigative Site
São Paulo, São Paulo, Brazil · Completed
Novartis Investigative Site
Varna, Bulgaria · Recruiting
Novartis Investigative Site
Montreal, Quebec, Canada · Recruiting
Novartis Investigative Site
Beijing, China · Active not recruiting
Novartis Investigative Site
Beijing, China · Recruiting
Novartis Investigative Site
Shanghai, China · Active not recruiting
Novartis Investigative Site
Shenyang, China · Recruiting
Novartis Investigative Site
Tianjin, China · Recruiting
Novartis Investigative Site
Chongqing, Chongqing Municipality, China · Recruiting
Novartis Investigative Site
Guangzhou, Guangdong, China · Recruiting
Novartis Investigative Site
Zhengzhou, Henan, China · Recruiting
Novartis Investigative Site
Wuhan, Hubei, China · Recruiting
Novartis Investigative Site
Changchun, Jilin, China · Recruiting
Novartis Investigative Site
Xian, Shanxi, China · Recruiting
Novartis Investigative Site
Chengdu, Sichuan, China · Completed
Novartis Investigative Site
Brno, Czechia · Recruiting
Novartis Investigative Site
Ostrava, Poruba, Czechia · Recruiting
Novartis Investigative Site
Copenhagen, Denmark · Completed
Novartis Investigative Site
Bordeaux, France · Recruiting
Novartis Investigative Site
Lyon, France · Recruiting
Novartis Investigative Site
Marseille, France · Recruiting
Novartis Investigative Site
Nantes, France · Recruiting
Novartis Investigative Site
Paris, France · Recruiting
Novartis Investigative Site
Vandœuvre-lès-Nancy, France · Recruiting
Novartis Investigative Site
Berlin, Germany · Recruiting
Showing 40 of 88 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.